[Cancer Management and Research] Retrospective review sought to determine how residual tumor diameter and number of cycles of adjuvant chemotherapy after surgery influenced prognosis for patients with OCCC.
[Journal of Hepatocellular Carcinoma] Researchers at UT MD Anderson Cancer Center assessed the value of chest, abdominal, and pelvic CT in the surveillance of patients with HCC, and the potential drawbacks to the practice.
[Breast Cancer: Targets and Therapy] This review focuses on alpelisib, a PI3K inhibitor, approved for the treatment of HR+/HER2 negative metastatic breast cancer in patients with a PIK3CA mutation who have received prior endocrine therapy.
[Breast Cancer: Targets and Therapy] This review focuses on understanding how breast cancer responds to treatment and how resistance develops.
[OncoTargets and Therapy] Investigators from the Mayo Clinic in Jacksonville, Florida, review treatment strategies for mCRPC using CDK4/6 inhibitors and combination therapies.
[Breast Cancer: Targets and Therapy] This review summarizes current knowledge of predictors and prognostic biomarkers of this rare and highly aggressive subtype of breast cancer.
[Cancer Management and Research] A review of how the multidisciplinary approach in cancer care influences adherence to clinical guidelines, treatment outcomes, and overall improvement in decision-making processes.
[Cancer Management and Research] Researchers seek to determine the effectiveness of comprehensive pulmonary rehabilitation in patients with risk factors undergoing surgery for lung cancer.
[OncoTargets and Therapy] Afatinib, an irreversible ErbB family blocker, may have a potential role as second- or third-line treatment for patients with lung cancer who experience disease progression on an immune checkpoint inhibitor and platinum-based chemotherapy regimen.
[Cancer Management and Research] This study was to establish models that respectively predict malignancy risk of incidental solid and subsolid pulmonary nodules of different size.
